Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug 25;11(8):e0160966.
doi: 10.1371/journal.pone.0160966. eCollection 2016.

Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients

Mark E Sherman  1 , Laura Ichikawa  2 , Ruth M Pfeiffer  3 , Diana L Miglioretti  2   4 , Karla Kerlikowske  5 , Jeffery Tice  6 , Pamela M Vacek  7 , Gretchen L Gierach  3
Affiliations

Relationship of Predicted Risk of Developing Invasive Breast Cancer, as Assessed with Three Models, and Breast Cancer Mortality among Breast Cancer Patients

Mark E Sherman et al. PLoS One. .

Abstract

Purpose: Breast cancer risk prediction models are used to plan clinical trials and counsel women; however, relationships of predicted risks of breast cancer incidence and prognosis after breast cancer diagnosis are unknown.

Methods: Using largely pre-diagnostic information from the Breast Cancer Surveillance Consortium (BCSC) for 37,939 invasive breast cancers (1996-2007), we estimated 5-year breast cancer risk (<1%; 1-1.66%; ≥1.67%) with three models: BCSC 1-year risk model (BCSC-1; adapted to 5-year predictions); Breast Cancer Risk Assessment Tool (BCRAT); and BCSC 5-year risk model (BCSC-5). Breast cancer-specific mortality post-diagnosis (range: 1-13 years; median: 5.4-5.6 years) was related to predicted risk of developing breast cancer using unadjusted Cox proportional hazards models, and in age-stratified (35-44; 45-54; 55-69; 70-89 years) models adjusted for continuous age, BCSC registry, calendar period, income, mode of presentation, stage and treatment. Mean age at diagnosis was 60 years.

Results: Of 6,021 deaths, 2,993 (49.7%) were ascribed to breast cancer. In unadjusted case-only analyses, predicted breast cancer risk ≥1.67% versus <1.0% was associated with lower risk of breast cancer death; BCSC-1: hazard ratio (HR) = 0.82 (95% CI = 0.75-0.90); BCRAT: HR = 0.72 (95% CI = 0.65-0.81) and BCSC-5: HR = 0.84 (95% CI = 0.75-0.94). Age-stratified, adjusted models showed similar, although mostly non-significant HRs. Among women ages 55-69 years, HRs approximated 1.0. Generally, higher predicted risk was inversely related to percentages of cancers with unfavorable prognostic characteristics, especially among women 35-44 years.

Conclusions: Among cases assessed with three models, higher predicted risk of developing breast cancer was not associated with greater risk of breast cancer death; thus, these models would have limited utility in planning studies to evaluate breast cancer mortality reduction strategies. Further, when offering women counseling, it may be useful to note that high predicted risk of developing breast cancer does not imply that if cancer develops it will behave aggressively.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Categories of predicted risk of developing breast cancer.
Fig 2
Fig 2. Predicted 5-year risk of developing breast cancer versus clinicopathologic characteristics.
Fig 3
Fig 3. Predicted risk of developing breast cancer versus risk of death (unadjusted).
Fig 4
Fig 4. Predicted risk of developing breast cancer versus risk of death (age-stratified, adjusted models).
Age-stratified models, adjusted for age in single years, registry, year of diagnosis, mode of detection, AJCC stage, treatment (surgery and chemotherapy: yes/no) and income (zip code of residence)
See this image and copyright information in PMC

References

    1. Allen SV, Solberg Nes L, Marnach ML, Polga K, Jenkins SM, Files JA, et al. Patient understanding of the revised USPSTF screening mammogram guidelines: need for development of patient decision aids. BMC women's health. 2012;12:36 10.1186/1472-6874-12-36 - DOI - PMC - PubMed
    1. Moyer VA, Force USPST. Medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine. 2013;159(10):698–708. 10.7326/0003-4819-159-10-201311190-00717 . - DOI - PubMed
    1. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA: the journal of the American Medical Association. 2014;311(13):1327–35. 10.1001/jama.2014.1398 . - DOI - PubMed
    1. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. Journal of the National Cancer Institute. 2009;101(6):384–98. 10.1093/jnci/djp018 - DOI - PMC - PubMed
    1. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Annals of internal medicine. 2008;148(5):337–47. - PMC - PubMed